Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Pharma Two B.

    Client Virtual Booth

    PHARMA TWO B

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Pharma Two B
    Israel Flag
    Country
    Country
    Israel
    Address
    Address
    3 Pekeris Street, Weizmann Science Park, Rehovot, 7670203
    Telephone
    Telephone
    +972-8-9472672
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://pharma2b.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Pharma Two B Presents Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at the MDS International Congress of Parkinson's Disease and Moveme...

    Details:

    P2B001 showed superior efficacy to each of its individual components in the trial and comparable efficacy to marketed doses of Pramipexole ER, but with reduced adverse events related to dopaminergic side effects and sleepiness, and with less worsening on the ESS.


    Lead Product(s): Pramipexole Dihydrochloride,Rasagiline Mesylate

    Therapeutic Area: Neurology Product Name: P2B001

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 15, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Pharma Two B Presents Late-Breaker Abstract on Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at American Academy of Neurology (AAN) Ann...

    Details:

    Results demonstrated that P2B001, a combination of dopamine agonist, pramipexole, and MAO-B inhibitor, rasagiline has symptomatic benefits comparable to higher doses of marketed pramipexole ER, yet with less dopaminergic side effects and significantly less daytime sleepiness.


    Lead Product(s): Pramipexole Dihydrochloride,Rasagiline Mesylate

    Therapeutic Area: Neurology Product Name: P2B001

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 05, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Pharma Two B to Host a Virtual KOL Event on Successful Phase III Study Results of P2B001 in Parkinson’s Disease (PD)

    Details:

    Results demonstrate P2B001 (pramipexole) distinctive combination of efficacy and enhanced safety, supporting its potential as a first-line treatment option for people with early PD.


    Lead Product(s): Pramipexole Dihydrochloride,Rasagiline Mesylate

    Therapeutic Area: Neurology Product Name: P2B001

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 20, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Pharma Two B Announces Licensing and Investment Agreement with Myung In Pharm (MIP) for P2B001 in South Korea

    Details:

    Under the terms of the agreement, Myung In Pharm will seek regulatory approval for P2B001 in South Korea and will manufacture, commercialize and distribute P2B001 in the region.


    Lead Product(s): Pramipexole Dihydrochloride,Rasagiline Mesylate

    Therapeutic Area: Neurology Product Name: P2B001

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Myung In Pharm

    Deal Size: $5.0 million Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement November 18, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search